Home » Thought Leadership » Blogs » Page 3

Blogs

Read our insights and commentary about pharmaceutical industry news and healthcare innovation globally. Subscribe to our monthly newsletter to keep up to date with our thought leadership, news, and updates.

Showing 5 of 57 posts
Novel Combinations Double the Trouble
May 25, 2021 | Blogs

Novel Combinations: Double the Trouble

Launching a novel combination therapy provides a unique set of challenges and opportunities when seeking to achieve positive pricing and access outcomes. In this article, CBPartners reviewed the pricing and access outcomes from prior novel immuno-oncology combinations and have developed considerations for manufacturers developing strategies for their future pipeline.

April 14, 2021 | Blogs

Interview Series with Leaders of DTx: Challenges & Opportunities for Commercialization

In this three-part series, CBPartners’ Digital Therapeutics & Health Technology Expertise Team interviews some of the leaders of the digital therapeutics (DTx) space to collect their thoughts on the current challenges and opportunities for DTx commercialization.

November 3, 2020 | Blogs

The Future of Cell Therapy: What’s Next?

New cell therapy technologies show blockbuster potential for improved accessibility and efficacy in a wide range of indications, though these therapies come with their own downfalls that healthcare systems will need to adapt to in order for these products to reach their full potential.

October 29, 2020 | Blogs

2020 USA Election & Drug Pricing Outlook

An analysis of the key drug pricing proposals in the 2020 USA Election in terms of political focus, party priorities, implementation feasibility, and potential risk to biopharma.

October 20, 2020 | Blogs

Digital Therapeutics as Digital Companions: Models for Effective Pharma Partnerships

Pharma and biotech companies should be prepared to make long-term investments in capability building, market development, and evidence generation to maximize the value of digital companions.